Clinical trials: Peripheral T-cell Lymphomas (PTCL), open to volunteers
Peripheral T Cell Lymphoma
Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
This is a Phase I, multicenter, non-randomized, open-label, dose-exploratory clinical study to evaluate the safety and tolerability of linperlisib combined with SHR2554 in the treatment of R/R PTCL, and to preliminary observe the…
- Trial name
- NCT06712173
- Testing
- linperlisib and SHR2554
- Volunteers
- 33 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of GNTbm-38 in adult patients with advanced solid tumors and R/R PTCL.
- Trial name
- NCT07842445
- Testing
- GNTbm-38
- Volunteers
- 70 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
PTCL
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.
The efficacy and safety of chidamide in first-line maintenance therapy for PTCL will be assessed through a retrospective case analysis.
- Trial name
- NCT05967949
- Testing
- chidamide
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Peripheral T-cell Lymphomas (PTCL)
Golidocitinib Combined With GemOx in RR PTCL
The objective of this study is to evaluate the efficacy and safety of golidocitinib in combination with the GemOx regimen in r/r PTCL
- Trial name
- NCT07279584
- Testing
- golidocitinib, GEMOX
- Volunteers
- 31 people
- Sponsor
- Ruijin Hospital
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
This is a phase I/II clinical trial to evaluate the efficacy and safety of Golidocitinib combined with Pomalidomide for relapsed/refractory peripheral T-cell lymphoma.
- Trial name
- NCT06855823
- Testing
- Golicitinib combined with Pomadomide
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sun Yat-sen University
Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.
- Conditions
- Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma
- Trial name
- NCT06151106
- Testing
- Chidamide combined with Duvillisib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Peripheral T Cells Lymphoma (PTCL)
Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of linperlisib combined with chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma
- Trial name
- NCT07139353
- Testing
- Linperlisib, Chidamide
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
PTCL-NOS
Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL
This is a single-arm, multi-cohort, multicenter, phase Ib/IIa clinical study designed to evaluate the safety and efficacy of Zeprumetostat (an EZH2 inhibitor) in combination with different therapeutic agents/regimens …
- Trial name
- NCT07724782
- Testing
- Zeprumetostat( an EZH2 inhibitor) + X
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Maintenance Treatment of Peripheral T-cell Lymphoma
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
This is a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating golidocitinib as maintenance therapy in adult patients with peripheral T-cell lymphoma (PTCL) who achieved complete response (CR) or…
- Trial name
- T-START-M1 (NCT07300514)
- Testing
- PET-CTandct- DNAdetection, golidocitinib
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Fudan University
T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This is an open-label, phase I/II study of duvelisib in combination with Venetoclax for patients with relapsed/refractory NHL. Duvelisib is an FDA approved, marketed product used to treat certain patients with leukemia and…
- Trial name
- NCT06810778
- Testing
- Duvelisib, Venetoclax
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Newly Diagnosed Peripheral T-cell Lymphoma
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
The goal of this clinical trial is to compare Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL. The main question it aims to answer are: •Whether Chi-BEAM improves patient survival compared to BEAM group…
- Trial name
- NCT05931263
- Testing
- C-BEAM Regimen, BEAM Regimen
- Where
- China
- Volunteers
- 104 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Peripheral T Cell Lymphoma
Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
This is a multicenter, randomized, double-blind, phase III clinical study comprising two arms: a golidocitinib group and a placebo group.
- Trial name
- T-START-M1 (NCT07414758)
- Testing
- golidocitinib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
PTCL, Refractory
Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL
To evaluate the safety and efficacy of Zeprumetostat-based combination therapy, selected according to genotyping results, in patients with primary refractory peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT07493330
- Testing
- Zeprumetostat+Azacitadine, Zeprumetostat+Decitabine, Zeprumetostat+Chidamide
- Volunteers
- 86 people
- Sponsor
- Ruijin Hospital
Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. These T-cell neoplasms account for approximately 10-15% of all lymphomas.
- Conditions
- Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
- Trial name
- NCT07535762
- Testing
- Aclarubicin, Cyclophosphamide, Vincristine
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Peripheral T-cell Lymphoma
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).
- Trial name
- NCT07234162
- Testing
- Golidocitinib, Chidamide, Gemcitabine
- Where
- 51 sites in China, Taiwan and 1 more
- Volunteers
- 218 people
- Sponsor
- Dizal Pharmaceuticals
Relapsed or Refractory Peripheral T-cell Lymphoma
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.
- Trial name
- NCT05833724
- Testing
- Chidamide
- Where
- 6 sites in Taiwan
- Volunteers
- 33 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
Newly Diagnosed Peripheral T-cell Lymphoma
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
This is a prospective, single arm, single center study to evaluate the efficacy and safety of Duvelisib combined with Chidamide in the treatment of newly diagnosed peripheral T-cell lymphoma.
- Trial name
- NCT05976997
- Testing
- Duvelisib, Chidamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Liling Zhang
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.
- Trial name
- NCT06909877
- Testing
- HH2853 Tablets
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Peripheral T-cell Lymphoma Targeted Therapy
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
This study is an open label, multicenter study. Subjects are randomized at a 1:1 ratio to receive either (arm A) azacitidine administered IH at day 1-5 and chidamide admistered twice a week for two weeks in combination with…
- Trial name
- NCT05678933
- Testing
- Azacitidine, Chidamide, Cyclophosphamide
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCL
Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
To evaluate the safety of adebrelimab combined with SHR2554 in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and NK/T-cell lymphoma (NKTCL), to determine the recommended Phase 2 dose (RP2D) of the…
- Trial name
- NCT07615283
- Testing
- Adebrelimab & SHR2554
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University